A next-generation Biotechnology company creating off-the-shelf cellular medicines for Cancer, Infectious Diseases, and Degenerative Diseases.
GX Acquisition Corp has entered into a definitive agreement with Celularity.
News from Celularity:
Celularity Inc. to Host Investor and Analyst Research & Development Day
Read More Event Will Be Hosted On-site and Aired Virtually Highlighting Research, Clinical and Commercial Progress FLORHAM PARK, N.J., April 22, 2024 (GLOBE NEWSWIRE) — Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today it will host an on-site and virtual Investor and Analyst Research…
Continue Reading Celularity Inc. to Host Investor and Analyst Research & Development Day
Celularity Abstract “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” Accepted at ORS Tendon Conference 2024
Read More FLORHAM PARK, N.J., April 18, 2024 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that its abstract entitled “Emerging Technologies for the Management and Protection of Tendon Injuries: Decellularized Placental Biomaterials” was accepted by the Orthopedic Research Society…
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products
Read More Expects the First Quarter of 2024 will be the 4th consecutive quarter of both sequential and quarter-on-quarter net sales growth Implements plan to reduce 2024 selling, general & administrative expenses (SG&A), executive cash compensation, reinforces management’s alignment of incentives with shareholders on corporate success FLORHAM PARK, N.J., April 15, 2024 (GLOBE NEWSWIRE) — Celularity…
Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells
Read More Company Presenting at ASGCT Annual Meeting FLORHAM PARK, N.J., April 08, 2024 (GLOBE NEWSWIRE) — Celularity Inc. (NASDAQ: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it will present in vitro data from its investigational natural killer (NK) cell therapy programs at this year’s American Society of Gene…
Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L
Read More Nationally Established Q Code Will Further Support the Use of Biovance® 3L by Physicians to Treat Wound Care Patients in Office Settings FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that the U.S. Centers for…
Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance® 3L
Read More Nationally Established Q Code Will Further Support the Use of Biovance® 3L by Physicians to Treat Wound Care Patients in Office Settings FLORHAM PARK, N.J., March 26, 2024 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that the U.S. Centers for…
[fts_twitter twitter_name=celularity tweets_count=6 cover_photo=no stats_bar=no show_retweets=no show_replies=no]